The pooled prevalence of Barrett's esophagus was 11.6% (95% CI, 8.1% to 16.4%; P<0.001). ... Studies published through January 2020 that reported any experiences or outcomes of Barrett's esophagus and bariatric surgery were included.
A systematic review and meta-analysis of Barrett's esophagus studies identified several factors that may predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma. ... Currently, GI societies' guidelines on [Barrett's esophagus]
Cumulative recurrence risk of any Barrett's esophagus within two years was 19%, with an additional risk of 49% over the next 8.6 years. ... In the study, 74% of Barrett's esophagus recurrences developed at the gastroesophageal junction, and of these, 24.1
Patients with stable nondysplastic Barrett's esophagus (NDBE) have a low risk of progression to high-grade dysplasia or esophageal adenocarcinoma, according to a population-based study in the Netherlands.
High-dose proton-pump inhibitors and aspirin appeared effective for chemoprevention in patients with Barrett's esophagus in one study, while another study found a positive association between human papillomavirus status ... One recent study tested
Highlights from the conference, held this past week in San Diego, included new research and clinical tips on stopping Barrett's esophagus surveillance, diet and environmental risk factors in patients with ... From Barrett's esophagus to inflammatory
Endoscopic eradication therapy plus reflux control associated with decreased Barrett's recurrence rates
Endoscopic eradication therapy (EET) plus effective reflux control is associated with very low rates of recurrence in patients with Barrett's esophagus. ... high-risk (defined as younger than age 50 with long-segment Barrett's esophagus or a first-degree